NDLI: New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.

Please wait, while we are loading the content...

Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU.

Use of propranolol for hypersexual behavior in an adolescent with autism.

Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.

Effect of tumor necrosis factor- inhibitors on drug-induced pancreatitis in inflammatory bowel disease.

Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Clinical and economic impact of a quality improvement initiative to enhance early recognition and treatment of sepsis.

Energy drink-induced acute kidney injury.

Improvement of a woman's alcohol-related dementia via off-label memantine treatment: a 16-month clinical observation.

The prevention of contrast-induced nephropathy.

Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulase-negative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy.

Bone health evaluation in a veteran population: a need for the Fracture Risk Assessment Tool (FRAX).

New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.

Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.

Impact of medication reconciliation and review on clinical outcomes.

Interventions to reduce medication errors in pediatric intensive care.

Extended-release hydrocodone: the devil in disguise or just misunderstood?

Year: 2014 Volume: 48 Issue: 6

Year: 2014 Volume: 48 Issue: 5

Year: 2014 Volume: 48 Issue: 4

Year: 2014 Volume: 48 Issue: 3

Year: 2014 Volume: 48 Issue: 2

Year: 2014 Volume: 48 Issue: 1

Year: 2013 Volume: 47

Year: 2012 Volume: 46

Year: 2011 Volume: 45

Year: 2010 Volume: 44

Year: 2009 Volume: 43

Year: 2008 Volume: 42

Year: 2007 Volume: 41

Year: 2003 Volume: 37

New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Carris, Nicholas Kutner, Sara Reilly-Rogers, Shane
Description	Country affiliation: United States Author Affiliation: Carris N ( University of Florida, Gainesville, FL, USA carris@ufl.edu.); Kutner S ( Sarasota Memorial Hospital, Sarasota, FL, USA.); Reilly-Rogers S ( CVS, Jacksonville, FL, USA.)
Abstract	OBJECTIVE: To review 2 recently approved therapies for vasomotor symptoms (VMSs) of menopause. DATA SOURCES: PubMed searches (June 2003 to May 2014) were conducted using the keywords paroxetine vasomotor and bazedoxifene vasomotor. References from relevant articles were reviewed for pertinent citations that were not identified in the PubMed search. STUDY SELECTION AND DATA EXTRACTION: Phase 3 clinical trials of recently approved hormonal and nonhormonal therapies for the treatment of VMSs of menopause were selected. Studies that evaluated the use of paroxetine mesylate or bazedoxifene (BZA)/conjugated estrogens (CEs) for VMSs were included. DATA SYNTHESIS: Four studies for BZA/CEs were identified. One published report of low-dose paroxetine mesylate was identified that was a combined analysis of 2 phase 3 studies. Both agents significantly decrease the incidence of hot flushes compared with placebo and are approved for the treatment of moderate to severe VMSs associated with menopause. BZA/CEs is only approved for women with an intact uterus. In all circumstances, the use of BZA/CEs should be limited to the shortest duration possible. Paroxetine mesylate was not studied head-to-head against hormone therapy, but the magnitude of its effect on VMSs is less than expected with hormone therapy. CONCLUSIONS: BZA/CEs is an effective hormonal therapy for treating VMSs in women with an intact uterus. Paroxetine mesylate is the first nonhormonal therapy that the FDA has approved for VMSs, making both viable options for the treatment of VMSs of menopause.
File Format	HTM / HTML
ISSN	10600280
Issue Number	10
Volume Number	48
e-ISSN	15426270
Journal	Annals of Pharmacotherapy
Language	English
Publisher	SAGE Publications
Publisher Date	2014-10-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmaceutical Science Estrogens, Conjugated (usp) Therapeutic Use Hot Flashes Drug Therapy Indoles Mesylates Paroxetine Vasomotor System Drug Effects Clinical Trials As Topic Drug Combinations Female Physiopathology Humans Menopause Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.

Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial

Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.

Effects of bazedoxifene, conjugated equine estrogens, and a tissue-selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys.

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.

Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.

Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.

Dapagliflozin propanediol, avanafil, and conjugated estrogens/bazedoxifene.

A tissue selective estrogen complex: a new horizon for menopausal symptoms.

New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.

Similar Documents

Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.

Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial

Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.

Effects of bazedoxifene, conjugated equine estrogens, and a tissue-selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys.

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.

Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.

Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review.

Dapagliflozin propanediol, avanafil, and conjugated estrogens/bazedoxifene.

A tissue selective estrogen complex: a new horizon for menopausal symptoms.

New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.